Advanced searches left 3/3

Ace Inhibitor - Springer Nature

Summarized by Plex Scholar
Last Updated: 10 September 2022

* If you want to update the article please login/register

Toxicity Study of 3-Thienylalanine- Ornithine-Proline (TOP) Using as Novel ACE Inhibitor

Angiotensin converting enzyme inhibitor is one of the most common anti-hypertension drugs for hypertension treatment. We had previously reported the results for pharmacological integrity and potency of a peptidomimetic compound, 3-Thienylalanine-Proline, a in-house facility that was previously published. We were further encouraged to investigate this compound's toxicological profile in in-vivo in sub-chronic dosing in a different dosage regime above its normal dose. We therefore wanted to investigate the toxicity study, which is the 28 days toxicity of our inhouse compound TOP, using the recommended OECD guidelines for safety. In this report, we have administered the dose ten times higher dose than the recommended dose. In conclusion, TOP showed promising pharmacological activity in this study with no signs of toxicity in animals.

Source link: https://doi.org/10.1007/s10989-022-10449-3

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions